Relevance of Nitric Oxide for Myocardial Remodeling

Overview

Journal Curr Heart Fail Rep

Publisher Current Science

Date 2007 Mar 28

PMID 17386181

Citations 20

Authors

Paul B Massion

Jean-Luc Balligand

Affiliations

Soon will be listed here.

Abstract

Endogenous myocardial nitric oxide (NO) may modulate the transition from adaptive to maladaptive remodeling leading to heart failure. In rodent models of pressure overload or myocardial infarction, the three NO synthase (NOS) isoforms were shown to play a neutral, protective, or even adverse role in myocardial remodeling, depending on the quantity of NO produced, the location of each NOS and their regulators, the prevailing oxidant stress and resultant NO/oxidant balance, as well as NOS coupling/dimerization. Beside neuronal NOS and--in specific conditions--inducible NOS isoforms, endothelial NOS (eNOS) exerts cardioprotective effects on pressure-overload, ischemia/reperfusion, and myocardial infarction-induced myocardial remodeling, provided the enzyme remains in a coupled state. Besides its effects on excitation-contraction coupling in response to stretch, eNOS acts as an "endogenous beta-blocker" by restoring the sympathovagal balance, opposing excessive hypertrophy as well as promoting vasodilatation and neoangiogenesis, thereby contributing to tissue repair. As eNOS was also shown to mediate the beneficial effects of cardiovascular drugs commonly used in patients with heart failure, strategies to increase its expression and/or coupled catalytic activity in the myocardium offer new therapeutic avenues for the treatment of this disease.

Citing Articles

Reactive Oxygen Species Induced Pathways in Heart Failure Pathogenesis and Potential Therapeutic Strategies.

Mongirdiene A, Skrodenis L, Varoneckaite L, Mierkyte G, Gerulis J Biomedicines. 2022; 10(3).

PMID: 35327404 PMC: 8945343. DOI: 10.3390/biomedicines10030602.

Autocrine Signaling in Cardiac Remodeling: A Rich Source of Therapeutic Targets.

Segers V, De Keulenaer G J Am Heart Assoc. 2021; 10(3):e019169.

PMID: 33470124 PMC: 7955414. DOI: 10.1161/JAHA.120.019169.

Differences in metabolic profiles between bicuspid and tricuspid aortic stenosis in the setting of transcatheter aortic valve replacement.

Xiong T, Liu C, Liao Y, Zheng W, Li Y, Li X BMC Cardiovasc Disord. 2020; 20(1):229.

PMID: 32423380 PMC: 7236099. DOI: 10.1186/s12872-020-01491-4.

Angiogenic Endothelial Cell Signaling in Cardiac Hypertrophy and Heart Failure.

Gogiraju R, Bochenek M, Schafer K Front Cardiovasc Med. 2019; 6:20.

PMID: 30895179 PMC: 6415587. DOI: 10.3389/fcvm.2019.00020.

Antioxidant bilirubin works in multiple ways to reduce risk for obesity and its health complications.

DiNicolantonio J, McCarty M, OKeefe J Open Heart. 2018; 5(2):e000914.

PMID: 30364545 PMC: 6196942. DOI: 10.1136/openhrt-2018-000914.

References

Li Q, Guo Y, Tan W, Stein A, Dawn B, Wu W . Gene therapy with iNOS provides long-term protection against myocardial infarction without adverse functional consequences. Am J Physiol Heart Circ Physiol. 2005; 290(2):H584-9. PMC: 3648984. DOI: 10.1152/ajpheart.00855.2005. View

Champion H, Georgakopoulos D, Takimoto E, Isoda T, Wang Y, Kass D . Modulation of in vivo cardiac function by myocyte-specific nitric oxide synthase-3. Circ Res. 2004; 94(5):657-63. DOI: 10.1161/01.RES.0000119323.79644.20. View

Das A, Xi L, Kukreja R . Phosphodiesterase-5 inhibitor sildenafil preconditions adult cardiac myocytes against necrosis and apoptosis. Essential role of nitric oxide signaling. J Biol Chem. 2005; 280(13):12944-55. DOI: 10.1074/jbc.M404706200. View

Bolli R, Manchikalapudi S, Tang X, Takano H, Qiu Y, Guo Y . The protective effect of late preconditioning against myocardial stunning in conscious rabbits is mediated by nitric oxide synthase. Evidence that nitric oxide acts both as a trigger and as a mediator of the late phase of ischemic preconditioning. Circ Res. 1997; 81(6):1094-107. DOI: 10.1161/01.res.81.6.1094. View

Wollert K, Drexler H . Regulation of cardiac remodeling by nitric oxide: focus on cardiac myocyte hypertrophy and apoptosis. Heart Fail Rev. 2002; 7(4):317-25. DOI: 10.1023/a:1020706316429. View

Morawietz H, Rohrbach S, Rueckschloss U, Schellenberger E, Hakim K, Zerkowski H . Increased cardiac endothelial nitric oxide synthase expression in patients taking angiotensin-converting enzyme inhibitor therapy. Eur J Clin Invest. 2006; 36(10):705-12. DOI: 10.1111/j.1365-2362.2006.01715.x. View

Jones S, Greer J, Kakkar A, Ware P, Turnage R, Hicks M . Endothelial nitric oxide synthase overexpression attenuates myocardial reperfusion injury. Am J Physiol Heart Circ Physiol. 2003; 286(1):H276-82. DOI: 10.1152/ajpheart.00129.2003. View

Massion P, Dessy C, Desjardins F, Pelat M, Havaux X, Belge C . Cardiomyocyte-restricted overexpression of endothelial nitric oxide synthase (NOS3) attenuates beta-adrenergic stimulation and reinforces vagal inhibition of cardiac contraction. Circulation. 2004; 110(17):2666-72. DOI: 10.1161/01.CIR.0000145608.80855.BC. View

Feng Q, Lu X, Jones D, Shen J, Arnold J . Increased inducible nitric oxide synthase expression contributes to myocardial dysfunction and higher mortality after myocardial infarction in mice. Circulation. 2001; 104(6):700-4. DOI: 10.1161/hc3201.092284. View

10.

Ruetten H, Dimmeler S, Gehring D, Ihling C, Zeiher A . Concentric left ventricular remodeling in endothelial nitric oxide synthase knockout mice by chronic pressure overload. Cardiovasc Res. 2005; 66(3):444-53. DOI: 10.1016/j.cardiores.2005.01.021. View

11.

Saraiva R, Minhas K, Raju S, Barouch L, Pitz E, Schuleri K . Deficiency of neuronal nitric oxide synthase increases mortality and cardiac remodeling after myocardial infarction: role of nitroso-redox equilibrium. Circulation. 2005; 112(22):3415-22. DOI: 10.1161/CIRCULATIONAHA.105.557892. View

12.

Elrod J, Greer J, Bryan N, Langston W, Szot J, Gebregzlabher H . Cardiomyocyte-specific overexpression of NO synthase-3 protects against myocardial ischemia-reperfusion injury. Arterioscler Thromb Vasc Biol. 2006; 26(7):1517-23. DOI: 10.1161/01.ATV.0000224324.52466.e6. View

13.

Balligand J . Heat shock protein 90 in endothelial nitric oxide synthase signaling: following the lead(er)?. Circ Res. 2002; 90(8):838-41. DOI: 10.1161/01.res.0000018173.10175.ff. View

14.

Hataishi R, Rodrigues A, Morgan J, Ichinose F, Derumeaux G, Bloch K . Nitric oxide synthase 2 and pressure-overload-induced left ventricular remodelling in mice. Exp Physiol. 2006; 91(3):633-9. DOI: 10.1113/expphysiol.2005.033068. View

15.

Ichinose F, Bloch K, Wu J, Hataishi R, Aretz H, Picard M . Pressure overload-induced LV hypertrophy and dysfunction in mice are exacerbated by congenital NOS3 deficiency. Am J Physiol Heart Circ Physiol. 2003; 286(3):H1070-5. DOI: 10.1152/ajpheart.00940.2003. View

16.

Petroff M, Kim S, Pepe S, Dessy C, Marban E, Balligand J . Endogenous nitric oxide mechanisms mediate the stretch dependence of Ca2+ release in cardiomyocytes. Nat Cell Biol. 2001; 3(10):867-73. DOI: 10.1038/ncb1001-867. View

17.

Landmesser U, Engberding N, Bahlmann F, Schaefer A, Wiencke A, Heineke A . Statin-induced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, left ventricular function, and survival after experimental myocardial infarction requires endothelial nitric oxide synthase. Circulation. 2004; 110(14):1933-9. DOI: 10.1161/01.CIR.0000143232.67642.7A. View

18.

Iwata A, Sai S, Nitta Y, Chen M, Dalesandro J, Thomas R . Liposome-mediated gene transfection of endothelial nitric oxide synthase reduces endothelial activation and leukocyte infiltration in transplanted hearts. Circulation. 2001; 103(22):2753-9. DOI: 10.1161/01.cir.103.22.2753. View

19.

Feron O, Dessy C, Desager J, Balligand J . Hydroxy-methylglutaryl-coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance. Circulation. 2001; 103(1):113-8. DOI: 10.1161/01.cir.103.1.113. View

20.

Oelze M, Daiber A, Brandes R, Hortmann M, Wenzel P, Hink U . Nebivolol inhibits superoxide formation by NADPH oxidase and endothelial dysfunction in angiotensin II-treated rats. Hypertension. 2006; 48(4):677-84. DOI: 10.1161/01.HYP.0000239207.82326.29. View